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Aims Due to superior exercise performance, athletes show higher blood pressure (BP) at peak exercise compared to
untrained individuals. Thus, higher reference values for peak exercise systolic and diastolic BP were reported specif-
ically for athletes. However, the prognostic significance of high blood pressure response (HBPR) to exercise has




One hundred and forty-one normotensive athletes with HBPR to exercise were compared to 141 normotensive
athletes with normal blood pressure response (NBPR) to exercise, matched for gender, age, body size, and type of
sport. All athletes were followed up for 6.5 ± 2.8 years. Over follow-up, no cardiac events occurred; 24 athletes
were diagnosed essential hypertension (8.5%). Specifically, 19 (13.5%) belonged to the HBPR compared with 5
(3.5%) in the NBPR group (P= 0.003). Kaplan–Meier analysis confirmed that the incidence of hypertension during
follow-up was higher in the HBPR group (log-rank v2 P-value = 0.009). Multivariable analysis by Cox proportional
hazard survival model showed that resting BP and HBPR at baseline evaluation were the strongest predictors of in-
cident hypertension (v2 for the model 30.099; P< 0.001). Specifically, HBPR was associated with a hazard ratio of
3.6 (95% confidence interval 1.3–9.9) of developing hypertension. Over follow-up exercise capacity, as well as mor-
phologic and functional cardiac parameters in athletes from both groups did not change significantly.
...................................................................................................................................................................................................
Conclusion The present study showed that an exaggerated BP response to exercise increased the risk for incident hyperten-
sion in highly trained and normotensive athletes over a middle-term period.
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Introduction
Exercise testing is commonly performed in young athletes to derive in-
formation regarding cardiovascular adaptations to effort and to detect
subclinical conditions, such as coronary artery anomalies or arrhythmo-
genic diseases.1–4 Assessment of blood pressure (BP) during exercise is
an integral part of the test and provides important haemodynamic infor-
mation with relevant clinical value, such as the hypotensive response in
patients with obstructive hypertrophic cardiomyopathy or valvular
heart diseases.5,6 Besides, an exaggerated BP response to exercise has
been reported as a prognostic factor for incident hypertension or car-
diovascular disease in the general population.7–11
Athletes are capable of a superior exercise performance com-
pared with sedentary subjects and the BP achieved at maximal exer-
cise has been reported to be higher compared with the general
population.4,12 However, it is not clear whether an exaggerated BP
* Corresponding author. Tel: þ41 76 238 6105, Fax: þ41 44 209 29 38, Email: stefanocasellimd@gmail.com
Published on behalf of the European Society of Cardiology. All rights reserved. VC The Author(s) 2018. For permissions, please email: journals.permissions@oup.com.



































































































response to exercise in highly trained athletes should be considered
a simple adaptation to superior exercise performance (with no clinic-
al significance), or may represent a mismatch of cardiac output and
peripheral vascular resistance, and expression of subclinical impair-
ment of vascular relaxation with potential adverse clinical
implications.2,9,12
We, therefore, planned the present study to evaluate the clinical
outcome, in terms of incident hypertension or cardiovascular events,




The present study was conducted at the Institute of Sports Medicine and
Science in Rome, which is the referral centre for the evaluation of Italian
competitive athletes before participating to National or International
competitions. Between January 2008 and December 2012, we evaluated
1937 athletes; of these, 61 were excluded because of cardiovascular
abnormalities (n= 3) or definite diagnosis of hypertension (n= 58)13,14;
therefore, the eligible population was composed of 1876 normotensive
healthy athletes.
To the scope of our investigation, we identified two groups of athletes:
(i) a group of 141 normotensive athletes with HBPR to exercise testing,
here defined as >220 mmHg in male and >200 mmHg in female for peak
systolic BP and/or >85 mmHg in male and 80 mmHg in female for peak
diastolic BP. These threshold values were derived from a large cohort of
elite athletes undergoing maximal exercise testing and corresponded to
the 95th percentile12; (ii) as a control group we identified 141 normoten-
sive athletes with normal blood pressure response (NBPR) to exercise.
The controls were selected from the same large database of athletes, by
matching 1:1 with the HBPR group in terms of gender, age (±1 year),
body surface area (BSA; ±0.02 m2), and type of sport participated. Type
of sport was defined as skill (n= 40), power (n= 36), mixed (n= 92), or
endurance (n= 114), as previously reported.15 All the athletes were of
Caucasian ethnicity.
Written informed consent was waived for all athletes undergoing a
standard clinical evaluation pursuant to Italian law and Institute policy.
The study design was approved by the Review Board of the Institute and
funded by the Italian National Olympic Committee.
Clinical evaluation
Cardiovascular evaluation included clinical history, physical examination,
and resting 12-lead electrocardiogram (ECG). Office resting BP was
measured by an experienced cardiologist in the sitting position, after at
least 5 min of rest and prior to the exercise test.13,14,16 Body height and
weight were obtained in each subject before exercise testing. Body sur-
face area and body mass index (BMI) were calculated.
Exercise testing
The exercise testing was performed on a bicycle ergometer (Cubestress
XR400, Cardioline SpA, Italy). The starting load was 0.5 W/kg, with sub-
sequent increase of 0.5 W/kg every 2 min until exhaustion, identified as
the time when the athlete was unable to maintain the power output des-
pite encouragement. Digital 12-lead ECG was monitored before the test,
continuously during the exercise, and for at least 5 min during the recov-
ery phase. To measure the BP in a reliable and consistent fashion over the
test, the patient was asked to put the left arm in an extended and relaxed
position with the hand over the doctor’s shoulder. Both systolic and
diastolic BPs were manually measured at rest, at every incremental step
until peak exercise and during recovery.12
Echocardiography
Two-dimensional and Doppler echocardiography was performed using
iE33 (Philips Medical System, Andover, MA, USA). Two-dimensional
measurements of left ventricular (LV) cavity, wall thickness, left atrium,
and aortic root diameters were performed according to the European
Association of Cardiovascular Imaging and American Society of
Echocardiography.17 Left ventricular mass was measured by Devereux’s
formula and normalized to BSA. Diastolic function was evaluated as previ-
ously reported and conformed to current recommendations.18
Follow-up
Athletes were followed-up according to our medical programme for elite
athletes.19 Data from the most recent clinical evaluation were reviewed.
Onset of hypertension was defined when BP was >_140/90 mmHg on at
least two consecutive measurements, or when a specific pharmacological
treatment was started.13,14 Cardiovascular events were considered any
of death, stroke, myocardial infarction, or coronary revascularization.
Statistical analysis
Continuous data were expressed as mean ± standard deviation and cat-
egorical data as number of observations and frequencies. Differences be-
tween groups were evaluated with unpaired t-test and Levene’s test for
the equality of variance; differences between proportions were calculated
by v2 test. Statistical significance was set for a P-value <0.05. Change in
measurements over time within the same subject was assessed by paired
samples t-test; additionally, difference in measurements at follow-up and
baseline evaluation was performed and average changes were compared
across groups with unpaired samples t-test.
The effect of HBPR on incident hypertension was assessed by Kaplan–
Meier analysis with log-rank test. Additionally, Cox proportional regres-
sion analysis was used to identify those variables that were associated
with incidence of hypertension. Factors with a univariate value of P< 0.05
were included in a stepwise multivariable logistic regression analysis.
Categorical variables included family history, smoking habit, and type of
sport. The impact of type of sport was assessed by a binary categorical
variable using N1 dummy variables, with skill disciplines chosen as the
reference value. For the multivariable analysis, resting systolic and diastol-
ic BP were recoded as ordinal variables with 5 mmHg increment.
Statistical analysis was performed with SPSS software (version 24; SPSS
Inc., Chicago, IL, USA).
Results
Baseline characteristics
The baseline and follow-up characteristics of athletes with HBPR and
controls are summarized in Table 1. The mean age at baseline evalu-
ation of the overall group was 26± 6 years and 66% were male. No
significant difference was found in terms of family history of hyperten-
sion (45 vs. 31; P= 0.060) or smoking habit (5 vs. 1; P= 0.099) be-
tween HBPR and NBPR groups. Both resting and exercise BP were
higher in the HBPR group at baseline evaluation, while peak bicycle
ergometer workload was not significantly different. In terms of car-
diac adaptations, echocardiography showed similar cardiac dimen-
sions in the two groups and no significant differences for LV systolic
and/or diastolic function.












Table 1 Baseline and follow-up characteristics of athletes with normal blood pressure response (NBPR) or high
blood pressure response (HBPR) to exercise
Parameters NBPR HBPR P-value
Age (years) 26.0 ± 5.9 25.9 ± 6.1 0.953
Follow-up 32.4 ± 6.5 32.5 ± 6.4 0.861
Difference 6.4 6.6 0.602
BSA (m2) 1.98 ± 0.22 1.99 ± 0.24 0.473
Follow-up 1.98 ± 0.23 2.01 ± 0.26 0.293
Difference (95% CI) 0.001 (-0.006 to 0.007) 0.11 (0.001–0.021)a 0.089
BMI (kg/m2) 23 ± 3 24 ± 3 0.106
Follow-up 23 ± 3 24 ± 4 0.051
Difference (95% CI) 0.13 (0.01–0.24)a 0.28 (0.08–0.48)a 0.203
Resting systolic BP (mmHg) 116 ± 11 121 ± 9 <0.001
Follow-up 117 ± 10 122 ± 12 <0.001
Difference (95% CI) 0.97 (-0.51 to 2.45) 0.79 (-1.12 to 2.69) 0.879
Resting diastolic BP (mmHg) 74 ± 8 77 ± 6 0.007
Follow-up 75 ± 8 77 ± 7 <0.001
Difference (95% CI) 0.30 (-0.74 to 1.33) 0.53 (-0.72 to 1.79) 0.770
Maximal workload (W) 257 ± 62 262 ± 61 0.429
Follow-up 261 ± 60 261 ± 60 0.962
Difference (95% CI) 4.03 (0.19–7.87)a -1.45 (-6.51 to 3.60) 0.089
Max systolic BP (mmHg) 185 ± 20 208 ± 22 <0.001
Follow-up 187 ± 19 203 ± 26 <0.001
Difference (95% CI) 1.25 (-1.13 to 3.63) -4.86 (-8.86 to -0.86)a 0.010
Max diastolic BP (mmHg) 74 ± 7 83 ± 9 <0.001
Follow-up 75 ± 8 82 ± 11 <0.001
Difference (95% CI) 1.21 (-0.18 to 2.61) -0.75 (-2.23 to 0.74) 0.059
Maximal wall thickness (mm) 10 ± 1 10 ± 1 0.294
Follow-up 10 ± 1 10 ± 1 0.235
Difference (95% CI) 0.06 (-0.02 to 0.15) 0.08 (-0.02 to 0.20) 0.760
LV cavity diameter (mm) 54 ± 5 54 ± 5 0.823
Follow-up 54 ± 4 54 ± 4 0.736
Difference (95% CI) 0.16 (-0.07 to 0.38) 0.10 (-0.20 to 0.41) 0.767
Ejection fraction (%) 64 ± 6 64 ± 6 0.876
Follow-up 65 ± 6 65 ± 5 0.442
Difference (95% CI) 0.83 (-0.17 to 1.84) 0.22 (-0.68 to 1.12) 0.368
Left atrial diameter (mm) 36 ± 4 36 ± 4 0.658
Follow-up 36 ± 4 36 ± 5 0.969
Difference (95% CI) 0.23 (-0.17 to 0.62) -0.01 (-0.71 to 0.69) 0.565
Aortic root diameter (mm) 31 ± 4 31 ± 4 0.884
Follow-up 32 ± 4 32 ± 4 0.719
Difference (95% CI) 0.56 (0.28–0.84)a 0.66 (0.36–0.96)a 0.635
LV mass index (g/m2) 102 ± 23 103 ± 21 0.779
Follow-up 103 ± 24 105 ± 21 0.650
Difference (95% CI) 0.60 (-0.92 to 2.11) 1.02 (-0.75 to 2.78) 0.720
E/A 1.9 ± 0.5 1.9 ± 0.5 0.981
Follow-up 1.87 ± 0.48 1.8 ± 0.5 0.476
Difference (95% CI) -0.03 (-0.08 to 0.03) -0.08 (-0.15 to -0.01)a 0.215
TDI e0 14 ± 2 14 ± 2 0.484
Follow-up 13 ± 4 14 ± 5 0.406
Difference (95% CI) -0.07 (-0.87 to 0.74) -0.32 (-0.89 to 0.25) 0.616
E/e0 6.1 ± 1.1 6.4 ± 1.4 0.101
Follow-up 6.3 ± 1.2 6.5 ± 1.4 0.363
Difference (95% CI) 0.11 (-0.09 to 0.31) 0.05 (-0.15 to 0.25) 0.660
First row for each parameter reports values at baseline evaluation, second row (follow-up) reports values at last follow-up evaluation, and third row (difference) reports the dif-
ference: follow-up value—baseline value, with 95% confidence interval.
BMI, body mass index; BP, blood pressure; BSA, body surface area; CI, confidence interval; LV, left ventricle; TDI, tissue Doppler imaging.
aFollow-up value significantly different compared to baseline with P< 0.05.





































































Average follow-up was 6.5 ± 2.8 years and not significantly different
between the two groups (P= 0.602). All athletes continued training
regularly and none was disqualified from competitions. No cardiac
events occurred, including death, stroke, myocardial infarction, or
coronary revascularization. Few athletes complained of symptoms
during follow-up (n= 15; 5%), including palpitations in 11 (recognized
as reciprocating atrioventricular node tachycardia in two, who under-
went successful radiofrequency ablation), vasodepressor, neuro-
mediated syncope in three, and hemicrania in one; overall incidence
of symptoms was not significantly different between groups (4% vs.
6%; P= 0.426).
During follow-up, 24 athletes (20 males and four females) were
diagnosed essential hypertension (8.5%); of these, 19 were in the
HBPR (13.5%) and five in the control group (3.5%; v2 t-test P val-
ue = 0.003; Figure 1). In terms of gender, incident hypertension
occurred in four females out of 48 (8.3%) in the HBPR group com-
pared with none in the control group (P= 0.041) and 15 males out of
93 (16%) in the HBPR group compared with 5 (5%) in the control
group (P= 0.018).
Kaplan–Meier analysis showed a higher incidence of hypertension
among the HBPR athletes (log-rank v2 P-value =0.009; Figure 2).
Consistently, pharmacological treatment (including angiotensin-
converting enzyme inhibitors in three, angiotensin receptor blocker
in three and beta-blocker in one) was more frequently started in ath-
letes within the HBPR group (n= 6) compared with controls (n= 1;
P< 0.001).
Of note, maximum exercise capacity was similar in both groups
and did not change significantly over the follow-up; in athletes with
HBPR we observed a trivial (but statistically significant) reduction in
peak systolic BP at the last evaluation, which was not seen in the con-
trol group. This reduction of peak systolic BP remained significant in
the HBPR group even after removing the small subset of athletes tak-
ing medications (peak systolic BP at baseline 208 ± 23 mmHg vs.
202 ± 26 mmHg at follow-up, P= 0.008; peak diastolic BP at baseline
83± 10 mmHg vs. 82 ± 10 mmHg at follow-up, P= 0.115). In terms of
cardiac morphology, both groups showed a minimal but significant
change in aortic root size, which did not differ significantly across
groups. No other morphologic or functional cardiac parameters
changed significantly over follow-up (Table 1).
Table 2 shows results from univariate and multivariable analyses.
Resting BP and HBPR at baseline evaluation were the strongest
predictors of incident hypertension (v2 for the model 30.099;
P< 0.001). Specifically, HBPR was associated with a hazard ratio of
3.6 (95% confidence interval from 1.30 to 9.93) of developing
hypertension.
Discussion
The most important finding of our study was that in young normo-
tensive athletes, an abnormally high systolic and/or diastolic BP re-
sponse to exercise testing was an independent and significant
predictor of incident hypertension, during an average follow-up of al-
most 7 years. Specifically, athletes with HBPR had a hazard ratio of
developing hypertension 3.6 times higher compared with those with
normal BP response during exercise.
Findings from our study further expand several previous observa-
tions reporting an association between hypertensive response to ex-
ercise and cardiovascular outcome and/or incident hypertension. A
meta-analysis by Schultz et al.,10 including 12 studies and >46 000 sub-
jects followed-up for 15± 4 years, reported that exaggerated BP re-
sponse at moderate exercise intensity was associated with a 36%
increase in cardiovascular events and mortality, independently of age,
gender, resting BP, and cardiac risk factors. A recent study by Berger
et al.20 on >7000 normotensive subjects reported that over a follow-
up period of 5 ± 3 years, almost 15% developed hypertension; specif-
ically, this risk was related to quartiles of peak systolic and diastolic
BP on exercise testing, with individuals in the fourth quartile having
35% probability of developing hypertension.
Of note, most of the studies published to date reported data
derived from general population, in the middle-age range, while less is
known regarding young individuals and specifically those involved in
regular and intensive training programmes.
Figure 1 Incidence of hypertension in athletes according to peak exercise blood pressure at baseline evaluation.
































































..In a previous study, we observed that athletes with HBPR to exer-
cise were most commonly engaged in endurance and mixed sporting
disciplines, had higher BMI and resting BP values, showed a higher de-
gree of LV remodelling on echocardiography and were able to attain
higher workload on exercise testing in comparison to those with nor-
mal BP response.12 In consideration of these findings, it was not clear
whether the higher BP values we observed at peak exercise were
related simply to the higher performance on bicycle ergometer and
could be considered an expression of a superior cardiac adaptation,
deprived of any clinical significance.
Our results showed that an exaggerated BP response to exercise
was associated with incident hypertension in 13.5% of athletes, com-
pared with only 3.5% in those with normal BP at exercise test.
Interestingly and potentially related to the young age at baseline
evaluation, the development of hypertension was observed in the
later phase of follow-up and, as shown in Figure 2, the separation of
curves occurred only 7 years after the baseline evaluation.
During the follow-up, we did not record any major adverse cardio-
vascular event, which was also likely related to the young age, and the
excellent cardiovascular fitness (as well as the low risk profile) of our
athlete’s population.21
Several mechanisms have been proposed to explain the excessive
increase in BP during exercise, including high-sympathetic tone,
decreased aortic distensibility, endothelial dysfunction, and increased
activation of the renin-angiotensin-aldosterone system.2,22,23 Shim
et al.24 reported different neuro-hormonal changes in normotensive
individuals with or without HBPR to exercise. They observed that an
exaggerated BP response to exercise was associated with increased
angiotensin II levels compared with those with NBPR; conversely, no
difference was found between groups in terms of rise of catechol-
amines, aldosterone, and plasma renin activity.
In a recent study, Tzemos et al.25 reported that an exaggerated BP
response was related to endothelial dysfunction, decreased proximal
aortic compliance, and increased neuro-hormonal activation, all condi-
tions able to predict future cardiovascular morbidity. Another possible
explanation could be related to masked hypertension, not clinically
evident during office evaluation but that may become overt during fol-
low-up.26 Eventually, pathophysiological mechanisms linking the exag-
gerated BP response to exercise and incident hypertension are not
yet fully understood and remain largely a matter of controversy.
An interesting observation on our study population (and other
previous reports) is that athletes with HBPR to exercise also
Figure 2 Kaplan–Meier analysis showing hypertension free sur-
vival of athletes according to normal blood pressure response or
high blood pressure response to exercise.
................................ ...................................
....................................................................................................................................................................................................................
Table 2 Results of univariate and multivariable analyses to identify variables associated with incident hypertension
Univariate Multivariable Hazard ratio (95% CI)
B P-value B P-value
Age (1 year) 0.06 0.072
Gender (male) -0.95 0.082
Power discipline 0.59 0.239
Mixed discipline -0.86 0.118
Endurance discipline -0.35 0.426
Family history 0.89 0.030
Body surface area (m2) 2.37 0.005
Body mass index (kg/m2) 0.16 <0.001
Resting SBP on baseline evaluation (5 mmHg) 0.46 <0.001 0.37 0.003 1.45 (1.13–1.85)
Resting DBP on baseline evaluation (5 mmHg) 0.77 <0.001 0.41 0.041 1.50 (1.02–2.22)
HBPR 1.21 0.015 1.28 0.014 3.59 (1.30–9.93)
For categorical variables, female gender, skill sports, negative family history, and normal blood pressure response to exercise were chosen as the reference condition. For systol-
ic and diastolic blood pressure, the B coefficient and hazard ratios refer to a 5 mmHg increase.
DBP, diastolic blood pressure; HBP, high blood pressure response to exercise; SBP, systolic blood pressure.


































































































presented higher resting BP at baseline evaluation, even though none
with overt hypertension. Miyai et al.8 reported that in individuals with
a high-normal resting BP and exaggerated increase of BP during exer-
cise the risk for future hypertension was increased by 2.3 times.
Therefore, a practical consequence is that individuals with high-
normal BP at rest may be better evaluated and risk stratified after the
exercise testing.
In consideration of the absence of events or major symptoms in
the follow-up, the identification of athletes with HBPR to exercise
should not raise concerns in terms of sport participation. We believe
it appropriate for these individuals to enter a periodical follow-up
programme with controls every 1–2 years. The overall cardiovascular
risk profile should be assessed, and lifestyle modification advised
including weight control, reduced intake of salt, supplements, alcohol,
and anti-inflammatory drugs; these recommendations are frequently
sufficient to achieve an optimal BP control in athletes.16 Additionally,
the timely identification and correction of risk factors in the early
phase of sport participation plays an important role in the context of
the cardiovascular prevention of the athlete in the long term: indeed,
at the end of their career, when the beneficial effects of intense exer-
cise may decrease, some athletes may further increase their overall
risk profile.27–29
Moreover, despite some individuals having developed hyperten-
sion, no significant changes in terms of cardiac remodelling occurred
during follow-up (except for a minimal increase in aortic root size,
likely related to the aging process). Therefore, the beneficial effects
of prolonged and continued exercise activity seem to (at least partial-
ly) counterweight the effects of hypertension on athlete’s heart.
It is worth mentioning that our investigation also presents certain
limitations, including the relatively young age of athletes at the most
recent evaluation, which justifies the low incidence of major symp-
toms or cardiovascular diseases. Our study population was entirely
comprised of Caucasian individuals and, therefore, our results should
not be extrapolated to different ethnic population such as Afro-
Caribbean or African athletes (where hypertension is more
prevalent).
We also acknowledge that due to the small sample size of our
population some risk factors, such as hypertensive family history and
cigarette smoking were not significantly related to incident hyperten-
sion. Finally, our protocol did not include cardiac magnetic resonance
imaging, and therefore, we were not able to confirm the recent find-
ing of focal areas of late gadolinium enhancement compatible with
areas of interstitial fibrosis in male triathletes with a history of exer-
cise induced hypertension.30
Conclusion
In conclusion, an exaggerated BP response to exercise in normoten-
sive athletes should not be disregarded as a benign adaptation to the
high-exercise performance but should be considered as a risk factor
for incident hypertension over a middle-term period.
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